Overview

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics of two formulations of MK-1006. The primary hypothesis of this study is that the MK-1006 area under the curve (0 to infinity) and maximum concentration after administration of a single 80 mg dose of the dry filled capsule (DFC) and film coated tablet (FCT) formulations of MK-1006 will be similar.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.